Your session is about to expire
← Back to Search
Nivolumab + Lenalidomide for Lymphoma
Study Summary
This trial studies the side effects and best dose of lenalidomide when given with nivolumab to treat patients with non-Hodgkin or Hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You currently have active tuberculosis.You are allergic to certain medications.You have another type of cancer that is getting worse or needs treatment.You had a specific type of transplant involving cells from another person and experienced Graft Versus Host Disease.You have an active lymphoma in your brain or spinal cord.You have a condition where your body's immune system attacks its own cells, and you needed strong medicine for it in the last 2 years.You have been diagnosed with Hodgkin's disease and it has come back or not responded to at least one round of chemotherapy.You have been diagnosed with classical or lymphocyte-predominant Hodgkin's disease.You must have tried at least one treatment before. If you have had a stem cell transplant, that's okay. But if you have already tried lenalidomide and it didn't work, you can't participate.You are able to carry out daily activities with little or no difficulty.Your blood and body chemistry levels are within the required range.You have a weakened immune system or are taking medications that lower your body's ability to fight off infections within the past week.You have received a certain type of cancer treatment within the past 2 weeks, or have not fully recovered from side effects of a treatment received more than 4 weeks ago.You have a specific type of B-cell non-Hodgkin lymphoma confirmed by a biopsy.You have a disease that can be measured or evaluated.You have a serious infection that needs to be treated with IV medication.You have a serious heart condition.You have already been treated with certain medications and your condition did not improve.You have a history of HIV, active hepatitis B, or active hepatitis C.You have a history of blood clots or a known risk of developing them.You have a specific type of B-cell non-Hodgkin lymphoma confirmed by a tissue sample.You must have tried at least one treatment before. If you've had a stem cell transplant, that's okay. But if you've already tried lenalidomide and it didn't work, you can't participate.
- Group 1: Treatment (lenalidomide, nivolumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Lenalidomide been examined in other research efforts?
"Lenalidomide first entered clinical trials in 2004 at the Midwest Center for Hematology Oncology. To date, there are 1142 concluded studies and 983 active ones, with some of these occurring around Atlanta."
What is the population size for this experimental treatment?
"Affirmative. According to clinicaltrials.gov, this medical experiment is actively in search of participants; it was published on February 14th 2017 and the latest update was May 31st 2022. 102 individuals need to be recruited from two different locations for data collection purposes."
Are there any remaining vacancies for participants in this trial?
"This clinical trial remains in the process of recruitment, as indicated on its listing on clinicaltrials.gov. This research project was first posted to the public domain on February 14th 2017 and has seen an update since May 31st 2022."
What medical conditions can be effectively addressed by lenalidomide?
"Lenalidomide is often prescribed to patients who have gone through multiple prior systemic chemotherapy regimens. Moreover, it has also been found to be effective in treating malignant neoplasms and skin conditions like unresectable melanoma and squamous cell carcinoma."
What is the primary mission of this clinical experiment?
"According to Bristol-Myers Squibb, the trial's sponsor, their primary outcome of measure over a 28 day period is Adverse Events' Incidence as defined by NCI CTCAE version 4. Additionally, Secondary Outcomes encompassing Overall Response Rate (ORR), Overall Survival (OS) and Complete Response Rate (CR) in patients will be monitored for this experiment."
Share this study with friends
Copy Link
Messenger